Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac

Status Completed

Clinical Trial Summary

To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection (EMB) and follow-up of cellular rejection in heart transplant in childhood.

Clinical Trial Description

Objectives To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.

Background Detection of cardiac rejection is a major problem in cardiac transplantation. Invasive screenings at predefined time intervals for cellular rejection with using endomyocardial biopsies are standard procedures. However, cardiac biopsies are distressing and risky and are also costly. Moreover, as the histological expression of allograft rejection is patchy, endomyocardial biopsies may lead to sampling error. Thus, as the sensitivity is low and variable (range for 40 to 95%), indication of biopsy is still of debate.

Materials and methods All patients who undergone cardiac transplant are potentially eligible. They will be prospectively included in the study. They will have both examinations, their routine endomyocardial biopsies and cardiac MRI. Histological diagnosis of cellular rejection is given by the BILLINGHAM classification which is used in daily practice. Diagnosis of rejection of cardiac MRI is defined by the association of hyperintensity on T2-weighted sequence, and on gadolinium-enhanced sequences including SSFP (study state free precession) and myocardial delayed enhancement. Both MRI parameters attest of the presence of myocardial oedema related to acute rejection. Myocardial oedema is also associated with segmental abnormalities of myocardial contraction which is assessed by both CMR-tagged sequence.

Written informed consent will be required from the patients. Institutional review board approval will also be required.

Expected results and clinical implications We expect to demonstrate that CMRI is effective for detection of cellular rejection with a high sensitivity (expected sensitivity>95%) as compared to cardiac biopsy. In that condition, cardiac MRI could replace the invasive biopsy for serial detection and follow-up of rejection in heart transplant. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Heart Transplant Rejection

Clinical Trial Details

NCT number	NCT01136135
Study type	Observational
Source	Assistance Publique - Hôpitaux de Paris
Contact
Status	Completed
Phase	N/A
Start date	February 2010
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05205551` - Prospera Test Evaluation in Cardiac Transplant (ProTECT)
Completed	`NCT06436027` - Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
Not yet recruiting	`NCT05732779` - Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients	N/A
Active, not recruiting	`NCT05064462` - TTV Viral Load in Heart Transplant Recipients
Recruiting	`NCT04973943` - Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
Completed	`NCT03477383` - A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation
Not yet recruiting	`NCT05772442` - Cardiac Transplant Metabolomics With and Without Rejection
Recruiting	`NCT04707872` - Trifecta-Heart cfDNA-MMDx Study
Recruiting	`NCT06064123` - Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
Active, not recruiting	`NCT04921774` - Research on Patients With Heart Transplantation
Recruiting	`NCT04226521` - Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy	N/A
Completed	`NCT03393793` - HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Completed	`NCT03833050` - The TOGETHER Project - Heart
Active, not recruiting	`NCT03373227` - Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen	Phase 2
Active, not recruiting	`NCT03695601` - Surveillance HeartCare® Outcomes Registry
Active, not recruiting	`NCT01397812` - Heartsbreath Test for Heart Transplant Rejection	N/A
Active, not recruiting	`NCT05184426` - MuLtimodality EvaluatiOn of aNtibody mEdiated Damage in Heart Transplantation (LEONE-HT)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Cardiac Transplant Rejection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms